At the time of writing, Kyverna Therapeutics Inc [KYTX] stock is trading at $8.72, down -4.80%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The KYTX shares have gain 3.20% over the last week, with a monthly amount drifted -19.41%, and not seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Previously, H.C. Wainwright upgraded its rating to Buy on May 27, 2025, and kept the price target unchanged to $5. On October 10, 2024, UBS initiated with a Buy rating and assigned a price target of $13 on the stock. Rodman & Renshaw started tracking the stock assigning a Buy rating and suggested a price target of $16 on October 09, 2024. H.C. Wainwright initiated its recommendation with a Neutral and recommended $8 as its price target on July 03, 2024. Wells Fargo started tracking with a Overweight rating for this stock on March 04, 2024, and assigned it a price target of $44. In a note dated March 04, 2024, Morgan Stanley initiated an Overweight rating and provided a target price of $40 on this stock.
For the past year, the stock price of Kyverna Therapeutics Inc fluctuated between $1.78 and $13.67. Currently, Wall Street analysts expect the stock to reach $29.5 within the next 12 months. Kyverna Therapeutics Inc [NASDAQ: KYTX] shares were valued at $8.72 at the most recent close of the market. An investor can expect a potential return of 238.3% based on the average KYTX price forecast.
Analyzing the KYTX fundamentals
To continue investigating profitability, this company’s Return on Assets is posted at -0.86, Equity is -0.78 and Total Capital is -1.12. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.03.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance.
Ratios To Look Out For
It is important to note that Kyverna Therapeutics Inc [NASDAQ:KYTX] has a current ratio of 5.16. Also, the Quick Ratio is 5.16, while the Cash Ratio stands at 1.01.
Transactions by insiders
Recent insider trading involved SEIDENBERG BETH C, Director, that happened on Dec 18 ’25 when 0.13 million shares were purchased. 10% Owner, Westlake BioPartners Opportuni completed a deal on Dec 18 ’25 to buy 0.13 million shares. Meanwhile, Chief Technology Officer Walker Karen Marie sold 23998.0 shares on Dec 15 ’25.
